Free tool
FAERS Monitor: Tecvayli
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761291 or its brand name (Tecvayli, Teclistamab-Cqyv). Reports on generic versions are filed under their own applications.
Reports
2,379
Serious
1,947
82% of reports
Hospitalization
578
Death reported
444
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- cytokine release syndrome582
- immune effector cell-associated neurotoxicity syndrome211
- off label use199
- death155
- infection136
- plasma cell myeloma131
- neutropenia116
- fatigue99
- pyrexia94
- pneumonia92
- covid-1988
- drug ineffective73
- diarrhoea65
- product dose omission issue57
- neuropathy peripheral52
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 11 |
| 2023 | 408 |
| 2024 | 616 |
| 2025 | 772 |
| 2026 | 572 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,780 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| immune effector cell-associated neurotoxicity syndromeSignal | 211 | 326.5 | 286.3 | 65,746 |
| cytokine release syndromeSignal | 582 | 264.1 | 245.8 | 148,036 |
| plasma cell myelomaSignal | 131 | 29.8 | 25.2 | 3,610 |
| infectionSignal | 136 | 8.3 | 7.1 | 873 |
| neutropeniaSignal | 116 | 7.5 | 6.3 | 656 |
| neuropathy peripheralSignal | 52 | 4.8 | 3.7 | 155 |
| covid-19Signal | 88 | 4.4 | 3.6 | 233 |
| pneumoniaSignal | 92 | 2.5 | 2.1 | 84 |
| pyrexiaSignal | 94 | 2.4 | 2.0 | 77 |
| off label useSignal | 199 | 2.0 | 1.8 | 104 |
| product dose omission issue | 57 | 1.7 | 1.3 | 16 |
| death | 155 | 1.6 | 1.4 | 35 |
| fatigue | 99 | 1.1 | 0.9 | 1 |
| diarrhoea | 65 | 0.9 | 0.7 | 1 |
| drug ineffective | 73 | 0.5 | 0.4 | 41 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.